Anaplastic thyroid carcinoma ranges from 1.3 to 9.8% of all thyroid cancers globally.
Mutations, amplifications, activation of oncogenes and silencing of tumour suppressor genes
contribute to its aggressive behaviour, and recent studies (eg microarrays, microRNAs) have
provided further insights into its complex molecular dysregulation. Preclinical studies have
identified numerous proteins over-or underexpressed that affect critical cellular processes,
including transcription, signalling, mitosis, proliferation, cell cycle, apoptosis and adhesion …